Dr. Anthony J. Armini, PhD., CEO of Implant Sciences, commented, “We are gratified that Implant has been awarded this contract by a well-known Fortune-500 technology company. We believe Implant has a well-respected reputation in the industry and a proven track record of developing specialty ion implantation equipment used in semiconductor applications and providing ion implantation services to semiconductor fabs. This project should enable the Company to leverage its extensive knowledge base in the development of equipment for ion implantation and apply this expertise to the ion implantation of a specialty substrate in a semiconductor application. We also look forward to the opportunity to grow our implantation service business with the addition of this valued customer and believe it can be leveraged for growth in other areas of our semiconductor division.”
About Implant Sciences
Implant Sciences, incorporated in 1984, is using its core ion technology to develop, manufacture and market products for the homeland security, semiconductor and medical device industries. The Company has developed and commercialized portable and bench-top detection devices to identify explosives which are distributed under the Quantum SnifferTM brand name. The Company also provides state of the art ion implantation and wafer analytical services for the semiconductor industry. The Company also develops, manufactures and sells radioactive products for the treatment of cancer, including sales of radioactive seeds for the treatment of prostate cancer and development of a new, FDA approved radioactive source for use in the treatment of breast cancer. For further details on the Company and its products please visit the Company’s website at www.implantsciences.com.
Implant Sciences believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties. Such statements are based on management's current expectations and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information you are encouraged to review Implant Sciences’ filings with the Securities and Exchange Commission, including its Annual Report on Form 10K for the period ended June 30, 2006 and Quarterly Report on Form 10Q for the period ended September 30, 2006. The Company assumes no obligation to update the information contained in this press release.
